Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Accumulated Expenses (2018 - 2023)

Marker Therapeutics (MRKR) has disclosed Accumulated Expenses for 7 consecutive years, with $610000.0 as the latest value for Q2 2023.

  • Quarterly Accumulated Expenses fell 61.02% to $610000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $610000.0 through Jun 2023, down 61.02% year-over-year, with the annual reading at $750000.0 for FY2022, 68.75% down from the prior year.
  • Accumulated Expenses for Q2 2023 was $610000.0 at Marker Therapeutics, up from $454000.0 in the prior quarter.
  • The five-year high for Accumulated Expenses was $2.4 million in Q3 2021, with the low at $323000.0 in Q4 2019.
  • Average Accumulated Expenses over 5 years is $1.2 million, with a median of $858000.0 recorded in 2020.
  • The sharpest move saw Accumulated Expenses surged 424.46% in 2020, then crashed 68.75% in 2022.
  • Over 5 years, Accumulated Expenses stood at $323000.0 in 2019, then soared by 424.46% to $1.7 million in 2020, then skyrocketed by 41.68% to $2.4 million in 2021, then plummeted by 68.75% to $750000.0 in 2022, then fell by 18.67% to $610000.0 in 2023.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $610000.0, $454000.0, and $750000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.